Section: Pet Bacteria

Canine Brucellosis: Reproductive Failure Diagnosis

Introduction

Canine brucellosis is a globally distributed, zoonotic bacterial infection caused primarily by Brucella canis. This Gram-negative, facultative intracellular coccobacillus is a major cause of reproductive failure in breeding kennels, manifesting as late-term abortion, embryonic resorption, infertility, and orchitis. The pathogen's tropism for reproductive tissues and its ability to establish chronic, often subclinical infections pose significant diagnostic challenges. Accurate and timely diagnosis is essential for implementing control measures, preventing kennel-wide outbreaks, and mitigating zoonotic transmission risk to veterinary personnel and owners. This article provides an exhaustive review of the pathophysiology of B. canis induced reproductive failure and the diagnostic modalities available for its detection.

Etiology and Pathogenesis

Brucella canis belongs to the genus Brucella within the family Brucellaceae. Unlike B. abortus or B. melitensis, B. canis is characterized by a rough lipopolysaccharide (R-LPS) phenotype, lacking the O-polysaccharide side chain present in smooth species [1, 2]. This structural difference has profound implications for serodiagnosis, as standard smooth Brucella antigens do not detect antibodies against B. canis.

The pathogenesis of reproductive failure begins with bacterial entry through mucous membranes of the oropharynx, conjunctiva, or genital tract. Following local invasion, B. canis is phagocytosed by macrophages and dendritic cells. The bacterium evades intracellular killing by inhibiting phagosome-lysosome fusion and replicating within the endoplasmic reticulum-derived compartment [3, 4]. This intracellular niche facilitates dissemination via the lymphatics and bloodstream, leading to bacteremia that typically persists for 6 to 64 months [5].

The tropism for reproductive tissues is mediated by the bacterium's affinity for erythritol, a sugar alcohol present in high concentrations in the placenta, fetal fluids, and epididymis of dogs [6]. In pregnant bitches, B. canis colonizes the chorioallantoic membrane, causing placentitis, necrosis, and subsequent abortion, typically between days 45 and 55 of gestation [7]. In males, the organism localizes to the epididymis, prostate, and testicular interstitium, inducing granulomatous inflammation, epididymitis, and testicular degeneration [8].

Clinical Manifestations of Reproductive Failure

Female Dogs

The hallmark clinical sign in the bitch is late-term abortion, often occurring without premonitory signs. Aborted fetuses may be autolyzed or fresh, and the bitch may exhibit a serosanguinous to purulent vaginal discharge for 1 to 6 weeks post-abortion [9]. Other manifestations include:

  • Embryonic resorption, presenting as apparent infertility or failure to conceive.
  • Prolonged intervals between estrus cycles.
  • Metritis and placentitis.
  • Birth of weak, nonviable puppies that die within 24 to 48 hours [10].

Importantly, bitches may appear clinically healthy between reproductive episodes, and the infection does not impair future fertility in all cases, although carrier status persists.

Male Dogs

In intact males, B. canis infection causes:

  • Scrotal dermatitis and epididymitis, often with scrotal edema and pain.
  • Testicular atrophy, particularly of the epididymis, leading to reduced sperm quality.
  • Prostatitis, which may be subclinical or associated with tenesmus and hematuria.
  • Orchitis with subsequent fibrosis and permanent infertility [11, 12].

Semen abnormalities include oligospermia, asthenospermia, teratospermia, and the presence of leukocytes and inflammatory cells. Spermatozoa may exhibit detached heads, coiled tails, and proximal cytoplasmic droplets [13].

Non-Reproductive Signs

Although reproductive failure is the primary presenting complaint, B. canis can cause non-reproductive signs including:

  • Discospondylitis, particularly in large-breed dogs, presenting with spinal pain and neurologic deficits.
  • Uveitis and endophthalmitis.
  • Lymphadenomegaly.
  • Polyarthritis and immune-mediated glomerulonephritis [14, 15].

These manifestations are more common in chronically infected animals and may be the only clinical signs in non-breeding dogs.

Diagnostic Approach

The diagnosis of canine brucellosis requires a combination of serological, molecular, and bacteriological methods. No single test possesses 100% sensitivity and specificity across all stages of infection. A diagnostic algorithm integrating multiple modalities is recommended.

Serological Testing

Serology detects the humoral immune response to B. canis and is the most commonly employed screening method. The rough phenotype necessitates the use of B. canis specific antigens.

Rapid Slide Agglutination Test (RSAT)

The RSAT uses a stained B. canis antigen to detect IgM and IgG antibodies. It is rapid, inexpensive, and suitable for in-clinic screening. However, false positives occur due to cross-reacting antibodies from other Gram-negative bacteria (e.g., Bordetella bronchiseptica, Pseudomonas aeruginosa, Escherichia coli) [16]. The test has moderate sensitivity (70-80%) and specificity (85-90%) in naturally infected dogs [17]. A positive RSAT should be confirmed with a more specific test.

2-Mercaptoethanol (2-ME) RSAT

The 2-ME RSAT incorporates 2-mercaptoethanol to reduce IgM, thereby eliminating false-positive reactions from non-specific IgM. This test is more specific than the standard RSAT and is used as a confirmatory assay. A positive 2-ME RSAT result is highly suggestive of active infection [18].

Agar Gel Immunodiffusion (AGID)

AGID detects antibodies against cytoplasmic antigens of B. canis. It is highly specific (greater than 99%) but less sensitive than agglutination tests, particularly in early infection [19]. AGID is useful as a confirmatory test following a positive RSAT.

Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA platforms offer quantitative detection of anti-B. canis antibodies. Indirect ELISAs using R-LPS or cytoplasmic protein antigens provide high sensitivity (90-95%) and specificity (95-98%) [20, 21]. The Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus provides a comparative framework for understanding antigen capture and indirect ELISA principles, though the target pathogen differs. Competitive ELISAs, which use monoclonal antibodies, further reduce cross-reactivity [22].

ELISA is the preferred serological method for large-scale screening and epidemiological studies. It can differentiate between IgG and IgM responses, aiding in the distinction between acute and chronic infection.

Molecular Diagnostics

Polymerase chain reaction (PCR) assays detect B. canis DNA directly from clinical samples. PCR offers high sensitivity and specificity and can identify infection before seroconversion or in chronically infected dogs with low antibody titers [23].

Target Genes

Common PCR targets include:

  • IS711: An insertion sequence present in multiple copies in the Brucella genome. IS711-based assays are highly sensitive and can detect as few as 10 colony-forming units (CFU) per reaction [24].
  • bcsp31: A gene encoding a 31-kDa immunogenic protein conserved across Brucella species. This target provides genus-level detection [25].
  • omp25 and omp2b: Outer membrane protein genes used for species-specific identification [26].

Sample Types

PCR can be performed on a variety of samples:

  • Whole blood (EDTA) during the bacteremic phase.
  • Vaginal or preputial swabs.
  • Semen.
  • Aborted fetal tissues (lung, liver, stomach contents).
  • Placenta.
  • Lymph node aspirates [27, 28].

Real-time PCR (qPCR) using fluorescent probes (e.g., TaqMan) allows quantification of bacterial load and is more sensitive than conventional PCR [29]. Multiplex PCR panels can simultaneously detect B. canis and other reproductive pathogens, such as Canine Herpesvirus and Brucella abortus [30].

Bacteriological Culture

Isolation of B. canis by culture remains the gold standard for definitive diagnosis. The bacterium is a slow-growing, fastidious organism requiring enriched media and a microaerophilic atmosphere with 5-10% CO2 [31].

Culture Media

  • Trypticase soy agar or Brucella agar supplemented with 5% sheep blood.
  • Selective media containing antibiotics (polymyxin B, bacitracin, cycloheximide) to inhibit contaminating flora [32].

Sample Processing

Samples should be collected aseptically. Blood cultures are most sensitive during the first 4 weeks post-infection. Tissue samples (placenta, fetal lung) should be homogenized before plating. Cultures are incubated at 37 degrees Celsius for up to 21 days, with colonies appearing as small, smooth, translucent, and later becoming rough [33].

Identification

Presumptive identification is based on colony morphology, Gram stain (small, Gram-negative coccobacilli), positive urease and oxidase reactions, and agglutination with B. canis specific antiserum [34]. Definitive identification requires PCR or matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) [35].

Culture sensitivity is variable, ranging from 50-90% depending on the sample type and stage of infection. Bacteremia is intermittent, and false-negative cultures are common in chronic infections [36].

Diagnostic Algorithm

The following Mermaid diagram illustrates a recommended diagnostic workflow for a dog presenting with reproductive failure.

flowchart TD
    A[Clinical Suspicion: Abortion, Infertility, Orchitis], > B{RSAT Screening}
    B, >|Negative| C[Low Probability: Consider Repeat in 4 Weeks]
    B, >|Positive| D[2-ME RSAT or AGID Confirmation]
    D, >|Negative| E[Probable False Positive: Consider ELISA]
    D, >|Positive| F[Seropositive: Active Infection Likely]
    F, > G{Confirm with PCR}
    G, >|Positive| H[Definitive Diagnosis: Canine Brucellosis]
    G, >|Negative| I[Consider Culture or Repeat PCR]
    I, > J[Positive Culture: Confirmed]
    I, > K[Persistent Negative: Re-evaluate Clinical Signs]
    H, > L[Implement Biosecurity and Treatment]

Interpretation of Results

A positive result on two different serological tests (e.g., RSAT and 2-ME RSAT, or RSAT and AGID) in a dog with compatible clinical signs is considered diagnostic [37]. PCR positivity in blood or reproductive samples confirms active infection. A negative PCR does not rule out infection, as bacterial shedding is intermittent. In such cases, culture of multiple samples over time may be necessary.

Serological titers do not correlate well with clinical severity or bacterial shedding. Chronically infected dogs may have low or undetectable antibody levels, necessitating molecular testing [38].

Differential Diagnoses

Reproductive failure in dogs has multiple etiologies. Key differentials include:

  • Canine Herpesvirus: Causes fetal death and abortion, typically in early to mid-gestation, with characteristic multifocal hepatic necrosis in fetuses.
  • Bacterial metritis: Secondary to E. coli, Streptococcus spp., or Mycoplasma spp., often associated with postpartum complications.
  • Progesterone deficiency: Leading to luteal insufficiency and pregnancy loss.
  • Chromosomal abnormalities: Resulting in embryonic resorption.
  • Trauma or stress: Inducing abortion in susceptible bitches [39, 40].

A thorough diagnostic workup should include serology for B. canis, PCR for Canine Herpesvirus, bacterial culture of vaginal discharge, and histopathology of aborted fetuses.

Zoonotic Considerations

Brucella canis is a zoonotic pathogen, though human infection is less common than with B. abortus or B. melitensis. Transmission occurs through direct contact with infected tissues, blood, urine, or vaginal discharge. Veterinary personnel, kennel workers, and owners of infected dogs are at increased risk [41].

Human disease is often mild and nonspecific, presenting with fever, headache, lymphadenopathy, and malaise. Severe complications such as endocarditis, osteomyelitis, and neurobrucellosis are rare but documented [42, 43]. Immunocompromised individuals are at higher risk for severe disease.

Diagnosis in humans relies on serology using B. canis specific antigens and PCR. Treatment requires prolonged combination antibiotic therapy with doxycycline and rifampin or an aminoglycoside [44].

Control and Prevention

In breeding kennels, control of canine brucellosis is based on:

  • Screening: All new dogs should be tested with RSAT and PCR before introduction.
  • Quarantine: Seropositive dogs should be isolated and removed from the breeding program.
  • Testing of all breeding animals: At least twice yearly.
  • Culling: Infected dogs are typically removed from the kennel to prevent transmission.
  • Environmental decontamination: B. canis is susceptible to 1% sodium hypochlorite, 70% ethanol, and 2% glutaraldehyde [45].

No effective vaccine is commercially available for B. canis in dogs. Experimental vaccines using live attenuated or subunit approaches have shown limited efficacy [46].

Future Directions

Advances in diagnostic technology are improving the detection of B. canis. Next-generation sequencing (NGS) and metagenomic approaches can identify Brucella DNA in complex samples without prior knowledge of the pathogen [47]. CRISPR-based diagnostics (e.g., SHERLOCK, DETECTR) offer rapid, point-of-care detection with high sensitivity and specificity [48]. Proteomic profiling using MALDI-TOF MS is being refined for direct identification of B. canis from clinical specimens [49].

Serological improvements include the development of recombinant antigens that eliminate cross-reactivity and the use of multiplex bead-based assays for simultaneous detection of multiple pathogens [50].

Conclusion

Canine brucellosis caused by Brucella canis remains a significant cause of reproductive failure in dogs worldwide. The diagnosis requires a systematic approach combining serological screening, molecular confirmation, and, when necessary, bacteriological culture. The limitations of each test necessitate the use of a diagnostic algorithm to maximize sensitivity and specificity. Early and accurate diagnosis is critical for implementing control measures, preventing kennel outbreaks, and reducing zoonotic risk. Continued research into rapid, point-of-care diagnostics and effective vaccines will further enhance the management of this challenging infection.

References

[1] Carmichael LE, Bruner DW. Characteristics of a newly recognized species of Brucella from dogs. Cornell Vet. 1968;58(4):579-592.

[2] Alton GG, Jones LM, Pietz DE. Laboratory techniques in brucellosis. Monogr Ser World Health Organ. 1975;(55):1-163.

[3] Celli J, de Chastellier C, Franchini DM, et al. Brucella evades macrophage killing via VirB-dependent sustained interactions with the endoplasmic reticulum. J Exp Med. 2003;198(4):545-556.

[4] Gorvel JP, Moreno E. Brucella intracellular life: from invasion to intracellular replication. Vet Microbiol. 2002;90(1-4):281-297.

[5] Carmichael LE, Kenney RM. Canine brucellosis: the clinical disease, pathogenesis, and immune response. J Am Vet Med Assoc. 1970;156(12):1726-1734.

[6] Keppie J, Williams AE, Witt K, et al. The role of erythritol in the tissue localization of the brucellae. Br J Exp Pathol. 1965;46(1):104-108.

[7] Moore JA, Kakuk TJ. Canine brucellosis: pathogenesis and clinical signs. J Am Vet Med Assoc. 1969;155(12):2002-2006.

[8] George LW, Carmichael LE. A systemic study of the pathology of Brucella canis infection in the dog. Cornell Vet. 1974;64(4):530-548.

[9] Hollett RB. Canine brucellosis: outbreaks and complications. Compend Contin Educ Pract Vet. 2006;28(4):262-272.

[10] Carmichael LE. Canine brucellosis: an annotated review with selected cautionary comments. Theriogenology. 1990;33(1):121-131.

[11] Lulich JP, Osborne CA, Polzin DJ, et al. Canine brucellosis: clinical features and diagnosis. Vet Clin North Am Small Anim Pract. 1993;23(5):1051-1068.

[12] Wanke MM. Canine brucellosis. Anim Reprod Sci. 2004;82-83:195-207.

[13] Kutzler MA, Holst BS. Canine brucellosis: a review. J Am Vet Med Assoc. 2012;241(8):1058-1064.

[14] Kerwin SC, Lewis DD, Hribernik TN, et al. Discospondylitis associated with Brucella canis infection in dogs: 14 cases (1980-1991). J Am Vet Med Assoc. 1992;201(8):1253-1257.

[15] Greene CE, Carmichael LE. Canine brucellosis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. Elsevier; 2012:398-408.

[16] Carmichael LE, Zoha SJ, Flores-Castro R. Problems in the serodiagnosis of canine brucellosis: dog responses to cell wall and internal antigens. Dev Biol Stand. 1984;56:371-383.

[17] Carmichael LE, Joubert JC, Pollock RV. A modified rapid slide agglutination test for the serodiagnosis of Brucella canis infection. J Am Vet Med Assoc. 1987;190(6):673-676.

[18] Badakhsh FF, Carmichael LE, Douglass JA. Improved rapid slide agglutination test for presumptive diagnosis of canine brucellosis. J Clin Microbiol. 1982;15(2):286-289.

[19] Myers DM, Jones LM, Varela-Diaz VM. Studies of antigens for complement fixation and gel diffusion tests in the diagnosis of Brucella canis infection. Appl Microbiol. 1972;23(5):894-902.

[20] Lucero NE, Escobar GI, Ayala SM, et al. Sensitivity and specificity of an indirect enzyme-linked immunoassay for the diagnosis of Brucella canis infection in dogs. J Med Microbiol. 2002;51(8):656-660.

[21] Wanke MM, Delpino MV, Baldi PC. Use of recombinant Brucella canis outer membrane protein 25 as a diagnostic antigen in ELISA for canine brucellosis. Vet Microbiol. 2009;136(1-2):157-162.

[22] Nielsen K, Smith P, Yu WL, et al. Validation of a second generation competitive enzyme immunoassay (CELISA) for the detection of antibodies to Brucella abortus in bovine sera. Vet Microbiol. 1999;68(3-4):195-204.

[23] Bricker BJ, Halling SM. Differentiation of Brucella abortus bv. 1, 2, and 4, Brucella melitensis, Brucella ovis, and Brucella suis bv. 1 by PCR. J Clin Microbiol. 1994;32(11):2660-2666.

[24] Hinic V, Brodard I, Thomann A, et al. Novel identification and differentiation of Brucella melitensis, B. abortus, B. suis, B. ovis, B. canis, and B. neotomae suitable for routine use. J Clin Microbiol. 2008;46(7):2240-2245.

[25] Baily GG, Krahn JB, Drasar BS, et al. Detection of Brucella melitensis and Brucella abortus by DNA amplification. J Trop Med Hyg. 1992;95(4):271-275.

[26] Cloeckaert A, Verger JM, Grayon M, et al. Restriction site polymorphism of the genes encoding the major 25 kDa and 36 kDa outer-membrane proteins of Brucella. Microbiology. 1995;141(Pt 9):2111-2121.

[27] Keid LB, Soares RM, Vasconcellos SA, et al. Comparison of agar gel immunodiffusion test, rapid slide agglutination test, microbiological culture and PCR for the diagnosis of canine brucellosis. Res Vet Sci. 2009;86(1):22-26.

[28] Kauffman LK, Bjork KE, Galloway RL, et al. Detection of Brucella canis in canine blood and urine samples using real-time PCR. J Vet Diagn Invest. 2014;26(4):543-548.

[29] Probert WS, Schrader KN, Khuong NY, et al. Real-time multiplex PCR assay for detection of Brucella spp., B. abortus, and B. melitensis. J Clin Microbiol. 2004;42(3):1290-1293.

[30] Bounaadja L, Albert D, Chenais B, et al. Real-time PCR for identification of Brucella spp.: a comparative study of IS711, bcsp31 and per target genes. Vet Microbiol. 2009;137(1-2):156-164.

[31] Alton GG, Jones LM, Angus RD, et al. Techniques for the Brucellosis Laboratory. INRA; 1988.

[32] Farrell ID. The development of a new selective medium for the isolation of Brucella abortus from contaminated sources. Res Vet Sci. 1974;16(3):280-286.

[33] Corbel MJ. Brucellosis: an overview. Emerg Infect Dis. 1997;3(2):213-221.

[34] OIE. Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Chapter 3.1.4: Brucellosis (Brucella canis). World Organisation for Animal Health; 2021.

[35] Lista F, Reubsaet FA, De Santis R, et al. Reliable identification of Brucella species by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Clin Microbiol. 2011;49(5):1954-1960.

[36] Carmichael LE. Brucella canis. In: Nielsen K, Duncan JR, eds. Animal Brucellosis. CRC Press; 1990:335-350.

[37] Johnson CA, Walker RD. Clinical signs and diagnosis of Brucella canis infection. Compend Contin Educ Pract Vet. 1992;14(6):763-772.

[38] Keid LB, Soares RM, Vasconcellos SA, et al. A polymerase chain reaction for detection of Brucella canis in vaginal swabs of naturally infected bitches. Theriogenology. 2007;68(9):1260-1270.

[39] Verstegen J, Dhaliwal G, Verstegen-Onclin K. Canine and feline pregnancy loss due to viral and non-infectious causes: a review. Theriogenology. 2008;70(3):461-470.

[40] Johnston SD, Root Kustritz MV, Olson PNS. Canine and Feline Theriogenology. Saunders; 2001.

[41] Lucero NE, Corazza R, Almuzara MN, et al. Human Brucella canis outbreak linked to infection in dogs. Epidemiol Infect. 2010;138(2):280-285.

[42] Young EJ. Human brucellosis. Rev Infect Dis. 1983;5(5):821-842.

[43] Pappas G, Akritidis N, Bosilkovski M, et al. Brucellosis. N Engl J Med. 2005;352(22):2325-2336.

[44] Solera J, Martinez-Alfaro E, Espinosa A. Recognition and optimum treatment of brucellosis. Drugs. 1997;53(2):245-256.

[45] Nicoletti P. Brucellosis. In: Beran GW, ed. Handbook of Zoonoses. 2nd ed. CRC Press; 1994:99-110.

[46] Moriyon I, Grillo MJ, Monreal D, et al. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet Res. 2004;35(1):1-38.

[47] Foster JT, Price LB, Beckstrom-Sternberg SM, et al. Genotyping of Brucella species using multilocus short-sequence-repeat (MLVA) analysis. J Clin Microbiol. 2009;47(3):687-693.

[48] Gootenberg JS, Abudayyeh OO, Lee JW, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science. 2017;356(6336):438-442.

[49] Karger A, Melzer F, Tomaso H, et al. Interlaboratory comparison of intact-cell matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for the identification of Brucella species. J Clin Microbiol. 2013;51(9):3038-3043.

[50] Christopher S, Umapathy BL, Ravikumar KL. Brucellosis: review on the recent trends in pathogenicity and laboratory diagnosis. J Lab Physicians. 2010;2(2):55-60.